Health News

Researchers with UCLA’s Jonsson Comprehensive Cancer Center have found that melanoma patients whose cancers are caused by mutation of the BRAF gene become resistant to a promising targeted treatment through another genetic mutation or the overexpression of a cell surface protein, both driving survival of the cancer and accounting for relapse.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, gene, Genetic, Pharmacy, Protein

Related posts

• Study pinpoints compounds that repress cancer gene’s activity (0)
  A research team pursuing one of the most commonly altered genes in cancer has laid a critical foundation for understanding this gene that could point the way toward developing drugs against it. A recent study of cancer genetics pointed to the gene MCL1, which encodes a protein that helps keep cells alive Read more [tags] Pharmacy News [...]
  
  
• Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
  Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations. Read [...]
  
  
• Major study shoots for personalized breast cancer drugs (0)
  Mutations in BCRA1 and BCRA2 genes are mainly associated with increased risk of breast cancer in women. Recently many other genetic variants have been found to be associated with breast cancer. Read more [tags] Pharmacy News [/tags]
  
  
• Like Burrs On Your Clothes, Molecule-Size Capsules Can Deliver Drugs By Sticking To Targeted Cells (0)
  It is now possible to engineer tiny containers the size of a virus to deliver drugs and other materials with almost 100 percent efficiency to targeted cells in the bloodstream. According to a new Cornell study, the technique could one day be used to deliver vaccines, drugs or genetic material to treat [...]
  
  
• FDA Approves New Test To Help Determine If Breast Cancer Patients Are Candidates For Herceptin Treatment (0)
  The U.S. Food and Drug Administration approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of [...]